Liver Damage in Patients with HCV/HIV Coinfection Is Linked to HIV-Related Oxidative Stress

Oxidative Medicine and Cellular Longevity

Volumn 2016, Issue , 2016, Pages

  Huang, Xiangbo ^a   Liang, Hua ^b   Fan, Xueying ^a   Zhu, Liyan ^a   Shen, Tao ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

Author keywords

[No Author keywords available]

Indexed keywords

PEPTIDES; ULTRASONICS;

CENTRAL CHINAS; CO-INFECTIONS; GLUTATHIONE PEROXIDASE; HIV INFECTION; LIVER DISEASE; LIVER ULTRASOUNDS; MALONDIALDEHYDE; SERUM CONCENTRATION;

OXIDATIVE STRESS;

GLUTATHIONE; GLUTATHIONE DISULFIDE; GLUTATHIONE PEROXIDASE; MALONALDEHYDE; ZINC;

ARTICLE; BLOOD DONOR; CHINA; CONTROLLED STUDY; END STAGE LIVER DISEASE; FOLLOW UP; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER INJURY; MAJOR CLINICAL STUDY; MIXED INFECTION; MORTALITY; OXIDATIVE STRESS; ULTRASOUND; ADULT; CD8+ T LYMPHOCYTE; COMPLICATION; DIAGNOSTIC IMAGING; DISEASE COURSE; FEMALE; LIVER; LIVER CIRRHOSIS; LIVER DISEASE; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; VIROLOGY;

ADULT; CD8-POSITIVE T-LYMPHOCYTES; CHINA; COINFECTION; DISEASE PROGRESSION; FEMALE; GLUTATHIONE; GLUTATHIONE PEROXIDASE; HEPATITIS C; HIV INFECTIONS; HUMANS; LIVER; LIVER CIRRHOSIS; LIVER DISEASES; MALE; MALONDIALDEHYDE; MIDDLE AGED; OXIDATIVE STRESS;

EID: 84971300494     PISSN: 19420900     EISSN: 19420994     Source Type: Journal    
DOI: 10.1155/2016/8142431     Document Type: Article

References (46)

1. R. Muller, "The natural history of hepatitis C: clinical experiences, " Journal of Hepatology, vol. 24, no. 2, supplement, pp. 52-54, 1996.
2. K. Messick, J. C. Sanders, J. J. Goedert, and M. E. Eyster, "Hepatitis C viral clearance and antibody reactivity patterns in persons with haemophilia and other congenital bleeding disorders, " Haemophilia, vol. 7, no. 6, pp. 568-574, 2001.
3. Z. Wu, K. Rou, and R. Detels, "Prevalence of HIV infection among former commercial plasma donors in rural eastern China, "Health Policy and Planning, vol. 16, no. 1, pp. 41-46, 2001.
4. W. Zhang, D. Hu, Y. Xi, M. Zhang, and G. Duan, "SpreadofHIV in one village in central China with a high prevalence rate of blood-borne AIDS, " International Journal of Infectious Diseases, vol. 10, no. 6, pp. 475-480, 2006.
5. T. Zhang, D. C. Tully, S. Zhou, and N. He, "Characteristics of HCV co-infection among HIV infected individuals from an area with high risk of blood-borne infections in central China, " PLoS ONE, vol. 9, no. 4, Article ID e94219, 2014.
6. R. Zhao, J. Peng, L. Tang et al., "Epidemiological distribution and genotype characterization of hepatitis C virus and HIV coinfection inWuhan, China, where the prevalence of HIV is low, " Journal of Medical Virology, vol. 85, no. 10, pp. 1712-1723, 2013.
7. T. Shen, X. Chen, W. Zhang et al., "A higher correlation of HCV core antigenwithCD4+ Tcell counts comparedwithHCVRNA in HCV/HIV-1 coinfected patients, " PLoS ONE, vol. 6, no. 8, Article ID e23550, 2011.
8. Y. Liu, T. Shen, C. Zhang, L. Long, Z. Duan, and F. Lu, "HIV co-infection accelerates decay of humoral responses in spontaneous resolvers of HCV infection, " Journal of Viral Hepatitis, vol. 21, no. 10, pp. 690-695, 2014.
9. H.-Z. Qian, Z. Yang, X. Shi et al., "Hepatitis C virus infection in former commercial plasma/blood donors in rural Shanxi Province, China: the China integrated programs for research on AIDS, " Journal of Infectious Diseases, vol. 192, no. 10, pp. 1694-1700, 2005.
10. H.-Z. Qian, S. H. Vermund, R. A. Kaslow et al., "Co-infection with HIV and hepatitis C virus in former plasma/blood donors: challenge for patient care in rural China, " AIDS, vol. 20, no. 10, pp. 1429-1435, 2006.
11. C. Zhang, W. Wang, M. Zhou et al., "The interaction of CD4 T-cell count and nevirapine hepatotoxicity in China: A change in national treatment guidelines may be warranted, " Journal of Acquired Immune Deficiency Syndromes, vol. 62, no. 5, pp. 540-545, 2013.
12. H. Valdez, D. Anthony, F. Farukhi et al., "Immune responses to hepatitis C and non-hepatitis C antigens in hepatitis C virus infected and HIV-1 coinfected patients, " AIDS, vol. 14, no. 15, pp. 2239-2246, 2000.
13. C. Carbonneil, V. Donkova-Petrini, A. Aouba, and L. Weiss, "Defective dendritic cell function in HIV-infected patients receiving effective highly active antiretroviral therapy: neutralization of IL-10 production and depletion of CD4+CD25+ T cells restore high levels of HIV-specific CD4+ T cell responses induced by dendritic cells generated in the presence of IFN-, " TheJournal of Immunology, vol. 172, no. 12, pp. 7832-7840, 2004.
14. Y. Liu, Q. Lv, J. Gao et al., "Coinfection with HIV-1 alleviates iron accumulation in patients with chronic hepatitis C virus infection, " PLoS ONE, vol. 9, no. 6, Article ID e98039, 2014.
15. X. Q. Shan, T. Y. Aw, and D. P. Jones, "Glutathione-dependent protection against oxidative injury, " Pharmacology and Therapeutics, vol. 47, no. 1, pp. 61-71, 1990.
16. J. Czuczejko, B. A. Zachara, E. Staubach-Topczewska, W. Halota, and J. kdziora, "Selenium, glutathione and glutathione peroxidases in blood of patients with chronic liver diseases, " Acta Biochimica Polonica, vol. 50, no. 4, pp. 1147-1154, 2003.
17. J. D. Hayes and L. I. McLellan, "Glutathione and glutathionedependent enzymes represent a co-ordinately regulated defence against oxidative stress, " Free Radical Research, vol. 31, no. 4, pp. 273-300, 1999.
18. A. Valenzuela, "The biological significance of malondialdehyde determination in the assessment of tissue oxidative stress, " Life Sciences, vol. 48, no. 4, pp. 301-309, 1991.
19. D. H. Shin, S. S. Martinez, M. Parsons, D. T. Jayaweera, A. Campa, and M. K. Baum, "Relationship of oxidative stress with HIV disease progression in HIV/HCV co-infected and HIV mono-infected adults in Miami, " International Journal of Bioscience, Biochemistry and Bioinformatics, vol. 2, no. 3, pp. 217-223, 2012.
20. W. Lin, G. Wu, S. Li et al., "HIVandHCVcooperativelypromote hepatic fibrogenesis via induction of reactive oxygen species and NFkappaB, " The Journal of Biological Chemistry, vol. 286, no. 4, pp. 2665-2674, 2011.
21. M. K. Baum, S. Sales, D. T. Jayaweera et al., "Coinfection with hepatitis C virus, oxidative stress and antioxidant status inHIVpositive drug users in Miami, " HIV Medicine, vol. 12, no. 2, pp. 78-86, 2011.
22. A. J. Sanyal, "AGA technical review on nonalcoholic fatty liver disease, " Gastroenterology, vol. 123, no. 5, pp. 1705-1725, 2002.
23. R. K. Sterling, E. Lissen, N. Clumeck et al., "Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection, " Hepatology, vol. 43, no. 6, pp. 1317-1325, 2006.
24. N. Tamaki, M. Kurosaki, K. Tanaka et al., "Noninvasive estimation of fibrosis progression overtime using the FIB-4 index in chronic hepatitis C, " Journal of Viral Hepatitis, vol. 20, no. 1, pp. 72-76, 2013.
25. A. H. A. Moustafa, E. M. M. Ali, T. M. Mohamed, and H. I. Abdou, "Oxidative stress and thyroid hormones in patients with liver diseases, " European Journal of Internal Medicine, vol. 20, no. 7, pp. 703-708, 2009.
26. F. J. T. Staal, M. Roederer, D. M. Israelski et al., "Intracellular glutathione levels in T cell subsets decrease in HIV-infected individuals, " AIDS Research and Human Retroviruses, vol. 8, no. 2, pp. 305-311, 1992.
27. M. Roederer, F. J. T. Staal, H. Osada, L. A. Herzenberg, and L. A. Herzenberg, "CD4 and CD8 T cells with high intracellular glutathione levels are selectively lost as the HIV infection progresses, " International Immunology, vol. 3, no. 9, pp. 933-937, 1991.
28. E. Rosenthal, G. Pialoux, N. Bernard et al., "Liver-related mortality in human-immunodeficiency-virus-infected patients between 1995 and 2003 in the French GERMIVIC Joint Study Group Network (MORTAVIC 2003 Study), " Journal of Viral Hepatitis, vol. 14, no. 3, pp. 183-188, 2007.
29. P. Cacoub, L. Geffray, E. Rosenthal, C. Perronne, P. Veyssier, and G. Raguin, "Mortality among human immunodeficiency virusinfected patients with cirrhosis or hepatocellular carcinoma due to hepatitis C virus in French departments of internal medicine/infectious diseases, in 1995 and 1997, " Clinical Infectious Diseases, vol. 32, no. 8, pp. 1207-1214, 2001.
30. M. Jones and M. Núñez, "HIV and hepatitis C co-infection: the role of HAART in HIV/hepatitis C virus management, " Current Opinion in HIV and AIDS, vol. 6, no. 6, pp. 546-552, 2011.
31. C. Tural, D. Fuster, J. Tor et al., "Time on antiretroviral therapy is a protective factor for liver fibrosis in HIV and hepatitis C virus (HCV) co-infected patients, " Journal of Viral Hepatitis, vol. 10, no. 2, pp. 118-125, 2003.
32. S. Verma, C.-H. Wang, S. Govindarajan, G. Kanel, K. Squires, and M. Bonacini, "Do type and duration of antiretroviral therapy attenuate liver fibrosis in HIV-hepatitis C virus-coinfected patients" Clinical InfectiousDiseases, vol. 42, no. 2, pp. 262-270, 2006.
33. M. S. Sulkowski, D. L. Thomas, S. H. Mehta, R. E. Chaisson, and R. D. Moore, "Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections, " Hepatology, vol. 35, no. 1, pp. 182-189, 2002.
34. I. Sanne, H. Mommeja-Marin, J. Hinkle et al., "Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects, " Journal of Infectious Diseases, vol. 191, no. 6, pp. 825-829, 2005.
35. F. W. N. M. Wit, G. J. Weverling, J. Weel, S. Jurriaans, and J. M. A. Lange, "Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy, " Journal of Infectious Diseases, vol. 186, no. 1, pp. 23-31, 2002.
36. P. Aukrust, F. Müller, A. M. Svardal, T. Ueland, R. K. Berge, and S. S. Frøland, "Disturbed glutathionemetabolism and decreased antioxidant levels in human immunodeficiency virus-infected patients during highly active antiretroviral therapy-potential immunomodulatory effects of antioxidants, " Journal of Infectious Diseases, vol. 188, no. 2, pp. 232-238, 2003.
37. S. K. Cribbs, D. M. Guidot, G. S. Martin, J. Lennox, and L. A. Brown, "Anti-retroviral therapy is associated with decreased alveolar glutathione levels even in healthy HIV-infected individuals, " PLoS ONE, vol. 9, no. 2, Article ID e88630, 2014.
38. G. Crespo, X. Forns, and M. Navasa, "Serum markers of liver fibrosis in patients with chronic hepatitis C infection. Prognostic value of noninvasive markers of fibrosis in liver transplantation, " Gastroenterologia y Hepatologia, vol. 35, supplement 2, pp. 17-22, 2012.
39. L. Castera, "Noninvasive methods to assess liver disease in patients with hepatitis B or C, " Gastroenterology, vol. 142, no. 6, pp. 1293. e4-1302. e4, 2012.
40. C.-T. Wai, J. K. Greenson, R. J. Fontana et al., "A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C, " Hepatology, vol. 38, no. 2, pp. 518-526, 2003.
41. A. A. M. Shaheen and R. P. Myers, "Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis C-related fibrosis: A systematic review, " Hepatology, vol. 46, no. 3, pp. 912-921, 2007.
42. Z.-H. Lin, Y.-N. Xin, Q.-J. Dong et al., "Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: An updated meta-analysis, " Hepatology, vol. 53, no. 3, pp. 726-736, 2011.
43. A. Loaeza-del-Castillo, F. Paz-Pineda, E. Oviedo-Cárdenas, F. Sánchez-ávila, and F. Vargas-Vorácková, "AST to platelet ratio index (APRI) for the noninvasive evaluation of liver fibrosis, " Annals of Hepatology, vol. 7, no. 4, pp. 350-357, 2008.
44. A. Vallet-Pichard, V. Mallet, B. Nalpas et al., "FIB-4: An inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and Fibrotest, " Hepatology, vol. 46, no. 1, pp. 32-36, 2007.
45. S. D. Holmberg, M. Lu, L. B. Rupp et al., "Noninvasive serum fibrosis markers for screening and staging chronic hepatitis C virus patients in a large US cohort, " Clinical Infectious Diseases, vol. 57, no. 2, pp. 240-246, 2013.
46. A. Bhaskar, M. Munshi, S. Z. Khan et al., "Measuring glutathione redox potential of HIV-1-infected macrophages, " The Journal of Biological Chemistry, vol. 290, no. 2, pp. 1020-1038, 2015.